Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Chiaki Nakaseko, MD PhD, Naoto Takahashi, MD PhD FJSIM, Kaichi Nishiwaki, MD PhD, Hitoshi Ogasawara, MD PhD, Hisashi Wakita, MD

Blood (2015) 126 (23): 4032.

https://doi.org/10.1182/blood.V126.23.4032.4032

Published: 2015

Journal Articles

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Naoto Takahashi, MD PhD FJSIM, Tetsuzo Tauchi, MDPhD, Kunio Kitamura, MD PhD, Koichi Miyamura, MD PhD, Yoshio Saburi, MD PhD, Yasuhiko Miyata, MD PhD, Yoshihiro Hatta, Fumihiko Kimura, MD, Satoru Takada, MD, Tetsuya Fukuda, MD PhD, Katsumichi Fujimaki, Maho Ishikawa, Itaru Matsumura, MDPhD, Noriko Usui, MD, PhD, Kensuke Usuki, MDPhD, Yukio Kobayashi, MD PhD, Tomoki Naoe, MD PhD

Blood (2015) 126 (23): 4035.

https://doi.org/10.1182/blood.V126.23.4035.4035

Published: 2015

Journal Articles

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Shinsuke Noguchi, MD, Hiroyoshi Nishikawa, MD, PhD, Hirobumi Saitoh, MD, PhD, Atsushi Ohshima, MD, PhD, Kenichi Sawada, MD, PhD, Shimon Sakaguchi, MD PhD, Naoto Takahashi, MD PhD FJSIM

Blood (2015) 126 (23): 2219.

https://doi.org/10.1182/blood.V126.23.2219.2219

Published: 2015

Journal Articles

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

Seiji Shida, MD, Naoto Takahashi, MD, PhD, FJSIM, Masatomo Miura, PhD, Takenori Niioka, PhD, Morio Matsumoto, MD, Masao Hagihara, MD, Mutsuhito Motegi, MD, PhD, Masaaki Kume, MD, PhD, Jun Kuroki, MD, PhD, Atsushi Kitabayashi, MD, PhD, Yoshiaki Hatano, MD, PhD, Atsushi Watanabe, MD, PhD, Naohito Fujishima, MD, PhD, Yoshihiro Kameoka, MD, PhD, Hiroyuki Tagawa, MD, PhD, Makoto Hirokawa, MD, PhD, Kenichi Sawada, MD, PhD

Blood (2012) 120 (21): 4921.

https://doi.org/10.1182/blood.V120.21.4921.4921

Published: 2012

Journal Articles

ABCG2 C.421C>A Is Associated with Higher Trough Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia.

Naoto Takahashi, MD, PhD, FJSIM, Masatomo Miura, PhD, Stuart A Scott, PhD, FACMG, Kenichi Sawada, MD, PhD

Blood (2009) 114 (22): 110.

https://doi.org/10.1182/blood.V114.22.110.110

Published: 2009

NARROW

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

ABCG2 C.421C>A Is Associated with Higher Trough Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan

Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Possibility of Lenalidomide Therapy and Determination of Its Ideal Dose for Patients with Relapsed or Refractory Multiple Myeloma

ABCG2 C.421C>A Is Associated with Higher Trough Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only